EcoDrugPlus

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSOTSG00005009895
Gene Symbol: ENPP2
3 Cross references
220 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSOTSG00005025124
Gene Symbol: ENPP2
3 Cross references
220 Possible Orthologues:

Egl Nine Homolog 3-Like

Ensembl ID : ENSOTSG00005039071
Gene Symbol: LOC112233429
3 Cross references
146 Possible Orthologues:

Egl Nine Homolog 3-Like

Ensembl ID : ENSOTSG00005017947
Gene Symbol: LOC112233429
3 Cross references
146 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSOTSG00005040259
Gene Symbol: EGLN1
1 Cross references
195 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSOTSG00005022704
Gene Symbol: EGLN1
3 Cross references
195 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSOTSG00005011070
Gene Symbol: EGLN3
1 Cross references
194 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSOTSG00005016658
Gene Symbol: EPAS1B
1 Cross references
205 Possible Orthologues:

Endothelial Pas Domain-Containing Protein 1-Like

Ensembl ID : ENSOTSG00005026875
Gene Symbol: LOC112260055
3 Cross references
205 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSOTSG00005017661
Gene Symbol: ECE1
1 Cross references
224 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSOTSG00005031971
Gene Symbol: EDNRAA
1 Cross references
201 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSOTSG00005015065
Gene Symbol: EDNRAA
1 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).